Forus, an AI platform for medicine, announced Tuesday that it raised $150 million in Series C funding at a $3 billion valuation.
Forus, previously known as Tandem, offers a platform that connects doctors, pharmacies, payers and biopharma. The company uses AI agents to handle the administrative work between a provider prescribing a medication and a patient starting treatment, including navigating insurance, financial assistance and pharmacy logistics. Providers in all 50 states use the platform to treat patients in 85% of U.S. residential zip codes, according to the announcement.
The $150 million Series C round was led by Bain Capital Ventures, with participation from Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures and SV Angel. In total, Forus has raised more than $300 million.
“Forus is becoming how new medicine reaches people in America,” said Kevin Zhang, general partner at Bain Capital Ventures, in a statement. “We have backed the company since its seed, and in that time the largest companies in medicine have turned to it to bring their newest medicines to patients. The next era of medicine will run on the AI-powered network Forus is building.”
With the financing, Forus is investing in three primary areas: deepening the platform with more AI agents and clinical models, expanding to all medical specialties and sites of care, and growing its technical and go-to-market teams, according to Sahir Jaggi, CEO of Forus.
Currently, one-third of patients prescribed medications for high-cost or complex conditions never receive their first dose, forcing providers to rely on older, more accessible treatments rather than newer therapies that may offer better outcomes and fewer side effects, Jaggi said.
“A single prescription can take up to 15 steps across insurance approvals, financial assistance, specialty pharmacy routing, and fulfillment,” Jaggi stated. “Forus consolidates all of it into one system. The process differs for every patient, drug, payer, and pharmacy, leaving clinical teams to coordinate fragmented organizations and systems while patients wait without knowing what is happening. For providers and clinical staff, Forus closes that gap by giving every prescription an AI agent that reasons through the patient’s clinical, insurance, and financial circumstances and takes the actions required to move the patient from prescription through treatment.”
Ultimately, the company aims to put the Forus platform in every doctor’s office across the U.S.
“Making the development, launch, and delivery of each medicine faster, less expensive, and more predictable should allow biopharma companies to invest in more medicines and more indications,” Jaggi said. “The larger opportunity is not simply helping today’s treatments reach more people; it is helping more of the science being discovered become treatment in the first place.”
Photo: Richard Drury, Getty Images
